We estimated the duration of each stage in the preclinical progression of serous ovarian tumors by dividing the prevalence of occult cancers at each stage by the incidence of clinically diagnosed serous ovarian cancer (irrespective of stage) in a population matched for age (45.7 y for prevalence; 46.9 y for incidence) and genetic risk (BRCA1 mutation carriers) [27]. Here, BRCA1 is linked to ovarian serous tumor.